We develop and employ novel molecular nano-imaging technologies in early disease diagnosis, precise phenotyping, and therapeutic intervention.
In the past decade, we established a novel in vivo nano-imaging technology that allows detection of single molecules in a living organism. This technology enables identification and validation of molecular biomarkers and is a powerful tool for subclinical detection and effective guidance of treatment. We are applying it to a wide range of diseases, including diabetes complications, and cancer. Our imaging technology is cost-effective and has a favorable safety profile that facilitates its translation to the clinic.
Type 1 and type 2 diabetes affect the health of the inner lining of blood vessels. People with diabetes often…